Real-world assessment of the efficacy and tolerability profile of JAK inhibitors in difficult-to-treat rheumatoid arthritis
Authors' conclusion
JAKi effectively reduced disease activity in D2TRA patients with the same extent as active non-D2TRA patients. Tolerability profiles were comparable, with outcomes largely dependent on the presence of age and/or cardiovascular risk factors.
Study context
- Population
- RA patients initiating a JAK inhibitors (JAKi) between 2018 and 2022
- Exposure
- JAKi in difficult-to-treat rheumatoid arthritis (D2TRA) vs active non-D2TRA RA
- Outcome
- Efficacy (DAS28 and DAS28-CRP reduction from baseline)
- Follow-up
- First visit (6 months following JAKi initiation)
Methodological detailsreal-world, clinical practice
- Real-world
- Clinical practice
Main finding
As reported in the abstract
- Significant and similar reduction in both groups, before and after adjustment (incl. number and exposure duration to previous targeted therapies)
Observational data: associations, not effects.
Further findings
- JAKi discontinuation · mean observation 20±10 months — Patients discontinuing JAKi (overall) · D2TRA vs Non-D2TRA · no significant difference in discontinuation rates
- 35 (42 %) · P = 0.36
DAS28 and DAS28-CRP between first visit (FV) and LV · last available visit up to December 2022
- Remained stable in both groups
Responders and remission or low disease activity · FV and LV
- Similar in both groups
JAKi discontinuation · mean observation 20±10 months
- Discontinuations due to inefficacy and side effects evenly distributed
Safety
Infections, herpes zoster, MI and VTE
- Higher likelihood in patients aged ≥65 years and/or with at least one cardiovascular risk factor
- 30/39, 77 %
- Frequency similar between groups
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →